topotecan has been researched along with 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dorigo, O; Eng, C; Fekete, M; Santiskulvong, C | 1 |
Fukuda, K; Imai, Y; Ueda, Y; Yamagishi, H; Yoshimori, M | 1 |
2 other study(ies) available for topotecan and 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
Article | Year |
---|---|
Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cell Line, Tumor; Chromones; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Morpholines; Ovarian Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Signal Transduction; Topotecan | 2012 |
The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
Topics: Androstadienes; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Morpholines; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Topotecan; Wortmannin | 2012 |